Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
228 hedge funds and large institutions have $4.71B invested in Amicus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 98 increasing their positions, 64 reducing their positions, and 29 closing their positions.
358% more call options, than puts
Call options by funds: $51.8M | Put options by funds: $11.3M
53% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 64
30% more capital invested
Capital invested by funds: $3.63B → $4.71B (+$1.08B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
10% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 29
9.28% more ownership
Funds ownership: 104.03% → 113.31% (+9.3%)
0% more funds holding
Funds holding: 228 → 228 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$181M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$87M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$63.9M |
| 4 |
JP Morgan Chase
New York
|
+$54.9M |
| 5 |
Blackstone Inc
New York
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$38.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$28.3M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$24M |
| 4 |
AG
Artal Group
Luxembourg
|
-$23.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$20.8M |
FOLD Hedge Fund Activity: Q4 2023 in Review
228 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2023, worth a combined $4.71B — up 30% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new FOLD positions and 29 closed out — a net gain of 3 holders — while 98 added to existing stakes and 64 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $181M. The largest seller was Janus Henderson Group, cutting an estimated $38.9M.
- 228 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $4.71B of Amicus Therapeutics stock for Q4 2023, up 30% quarter-over-quarter.
- 32 funds opened new Amicus Therapeutics positions in Q4 2023 and 29 closed out, a net change of +3 holders.
- The largest Amicus Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $181M added.
- The largest Amicus Therapeutics seller in Q4 2023 was Janus Henderson Group, an estimated $38.9M sold.
Based on aggregated 13F filings for Q4 2023.